Search clinical trials for: sHPT

Total 37 results

Shanghai Hengrui Pharmaceutical Co., Ltd.

Recruiting

Investigating the Safety and Efficacy of SHR6508 Injection in the Treatment of Secondary Hyperparathyroidism in Hemodialysis Patients : A Multicenter, Long-term Clinical Trial

Secondary Hyperparathyroidism (SHPT) in Subjects With Chronic Kidney Disease (CKD) on Hemodialysis

China
First Affiliated Hospital Xi'an Jiaotong University

Recruiting

A Study on Prevention Strategies for CKD-SHPT and Related Complications Based on General Vitamin D Supplementation

Vitamin D Deficiency | Chronic Kidney Disease 5D | Secondary Hyperparathyroidism Due to Renal Causes

China
AbbVie

Recruiting

A Study to Evaluate Safety, Efficacy and Pharmacokinetics of Paricalcitol For Treatment of Secondary Hyperparathyroidism (SHPT) in Pediatric Participants With Stage 5 Chronic Kidney Disease (CKD)

Chronic Kidney Disease (CKD) | Secondary Hyperparathyroidism (SHPT)

United States, Puerto Rico
Amgen

Recruiting

A Phase 3 Study of Etelcalcetide in Children With Secondary Hyperparathyroidism Receiving Hemodialysis

Secondary Hyperparathyroidism

Spain, Belgium, Germany, Czechia, Poland, France, Greece, Hungary, Italy, United Kingdom, Lithuania, Portugal
Amgen

Recruiting

A Study of Etelcalcetide in Pediatric Subjects With Secondary Hyperparathyroidism and Chronic Kidney Disease on Hemodialysis

Chronic Kidney Disease | Secondary Hyperparathyroidism

Korea, Republic of, United States, Turkey, India, Singapore, Taiwan, Argentina, Malaysia, Russian Federation, Ukraine
Kyowa Kirin China Pharmaceutical Co., Ltd.

Completed

Efficacy and Safety of Cinacalcet in Ca, P and iPTH Levels in Patients With Mild, Moderate and Severe SHPT (ACTIVE)

Hyperparathyroidism; Secondary, Renal

China
Vifor (International) Inc.

Active, not recruiting

RAYALDEE Non Interventional Study (NIS) on Effectiveness in ND-CKD SHPT Patients (PORTRAY)

Chronic Kidney Disease

Germany
Astellas Pharma Inc

Completed

A Study to Evaluate the Effect of ASP7991 in Secondary Hyperparathyroidism Patients Undergoing Hemodialysis

Secondary Hyperparathyroidism

Japan
OPKO Health, Inc.

Active, not recruiting

Safety, Efficacy, PK and PD of CTAP101 (Calcifediol) ER Capsules for SHPT in HD Patients VDI

Chronic Kidney Diseases | Vitamin D Deficiency | Stage 5 Chronic Kidney Disease | Secondary Hyperparathyroidism Due to Renal Causes

United States
Amgen

Completed

Head-to-Head Study of Etelcalcetide and Cinacalcet in Asian Hemodialysis Patients With Secondary Hyperparathyroidism (SHPT)

Chronic Kidney Disease | Secondary Hyperparathyroidism

Korea, Republic of, Taiwan, Hong Kong, China, India, Malaysia
Shanghai Zhongshan Hospital

Unknown

Preemptive and Precise Intervention for CKD-SHPT

Hyperparathyroidism; Secondary, Renal
Amgen

Completed

Extension Study of Cinacalcet for Treatment of Secondary Hyperparathyroidism (SHPT) in Pediatric Patients With Chronic Kidney Disease on Dialysis

Secondary Hyperparathyroidism, Chronic Kidney Disease

United States, Czechia, Germany, France, Hungary, Greece, Belgium, Italy, Poland, Russian Federation, Ukraine
Amgen

Terminated

Efficacy and Safety of Cinacalcet in Pediatric Patients With Secondary Hyperparathyroidism (SHPT) and Chronic Kidney Disease (CKD) on Dialysis

Chronic Kidney Disease, Secondary Hyperparathyroidism

United States, Belgium, Italy, Hungary, Czechia, France, Germany, Greece, Spain, Poland, Russian Federation, Ukraine, New Zealand, Slovakia, Lithuania, Portugal
Amgen

Completed

Efficacy and Safety of Etelcalcetide (AMG 416) in the Treatment of Secondary Hyperparathyroidism (SHPT) in Patients With Chronic Kidney Disease on Hemodialysis

Hyperparathyroidism, Secondary

United States, Belgium, Italy, United Kingdom, Canada, Germany, Spain, Austria, Czechia, Hungary, France, Israel, Poland, Australia, Russian Federation
Amgen

Completed

Efficacy and Safety of Etelcalcetide (AMG 416) in the Treatment of Secondary Hyperparathyroidism (SHPT) in Patients With Chronic Kidney Disease (CKD) on Hemodialysis

Hyperparathyroidism, Secondary

United States, Belgium, Canada, France, Australia, Israel, Czechia, Hungary, Netherlands, Spain, Poland, Russian Federation, Italy, Sweden, Germany
Amgen

Completed

Head-to-Head Study of Etelcalcetide (AMG 416) and Cinacalcet

Chronic Kidney Disease | Secondary Hyperparathyroidism

United States, Italy, Belgium, Denmark, Switzerland, Canada, Turkey, Spain, Austria, Germany, Hungary, Greece, France, Poland, Russian Federation, Czechia, Latvia, Lithuania, New Zealand, Portugal, Sweden, Estonia
Amgen

Completed

A Single-dose Study in Paediatric Patients Aged 2 to Less Than 18 Years With Secondary Hyperparathyroidism (sHPT) Receiving Haemodialysis

Chronic Kidney Disease, Secondary Hyperparathyroidism

Belgium, United States, Germany, Poland, United Kingdom, Lithuania
Amgen

Completed

Extension Study of Etelcalcetide in the Treatment of Secondary Hyperparathyroidism (SHPT) in Patients With Chronic Kidney Disease (CKD) on Hemodialysis

Hyperparathyroidism, Secondary

United States, Belgium, Italy, United Kingdom, Canada, Germany, Spain, Australia, Austria, Israel, Czechia, Hungary, Netherlands, Poland, France, Russian Federation, Sweden
Amgen

Completed

Compare the Efficacy of Cinacalcet vs Traditional Vitamin D for Secondary Hyperparathyroidism (SHPT) Among Subjects Undergoing Hemodialysis

Hyperparathyroidism, Secondary
Amgen

Completed

Study to Assess the Impact on Calcium Levels When Hemodialysis Patients With Secondary Hyperparathyroidism (SHPT) Switch From Cinacalcet to Etelcalcetide

Hyperparathyroidism, Secondary

United States
Amgen

Completed

Extension Study of Etelcalcetide for Treatment of Secondary Hyperparathyroidism in Patients With Chronic Kidney Disease on Hemodialysis

Hyperparathyroidism, Secondary

United States, Belgium, Italy, Switzerland, Canada, Turkey, Spain, Australia, Austria, Israel, Czechia, Hungary, Poland, France, Russian Federation, Germany, Denmark, Greece, Latvia, Lithuania, Netherlands, New Zealand, Portugal, Sweden
OPKO Health, Inc.

Completed

Safety/Efficacy Study of CTAP101 in Chronic Kidney Disease Subjects With Secondary Hyperparathyroidism (SHPT)

Chronic Kidney Disease | Secondary Hyperparathyroidism | Vitamin D Insufficiency

United States
AbbVie (prior sponsor, Abbott)

Completed

A Study to Follow-up Patients With End Stage Renal Disease Undergoing Hemodialysis, Receiving Selective Vitamin D Receptor Activator's for Prevention and Treatment of Secondary Hyperparathyroidism

End Stage Renal Disease | Secondary Hyperparathyroidism

Turkey
AbbVie (prior sponsor, Abbott)

Completed

Long-Term Therapy Outcomes When Treating Chronic Kidney Disease (CKD) Patients With Paricalcitol in German and Austrian Clinical Practice (TOP)

Secondary Hyperparathyroidism | Kidney Insufficiency

Austria, Germany
OPKO IP Holdings II, Inc.

Completed

Comparison of I.V. CTAP201 and Doxercalciferol (Hectorol) in Subjects With Chronic Kidney Disease (CKD) and Secondary Hyperparathyroidism (SHPT)

Chronic Kidney Disease | Secondary Hyperparathyroidism | Chronic Renal Failure | Chronic Renal Insufficiency

United States
OPKO Health, Inc.

Withdrawn

Four Week, Pharmacodynamic/Pharmacokinetic, Efficacy, and Safety Study of Lunacalcipol (CTA018) (2007)

Secondary Hyperparathyroidism (SHPT) | Stage 5 Chronic Kidney Disease (CKD) | Hemodialysis (HD)
AbbVie (prior sponsor, Abbott)

Completed

Evaluation of Treatment With Zemplar Capsules in the Therapy of Secondary Hyperparathyroidism (SHPT)

Chronic Kidney Disease | Secondary Hyperparathyroidism

Bulgaria, Czech Republic, Romania
Washington University School of Medicine
Abbott; NorthShore University HealthSystem; Northwestern University Feinberg... and other collaborators

Completed

Paricalcitol Versus Calcitriol for Efficacy and Safety in Stage 3/4 Chronic Kidney Disease (CKD) With Secondary Hyperparathyroidism (SHPT) (PACE)

Chronic Kidney Disease | Secondary Hyperparathyroidism

United States
AbbVie (prior sponsor, Abbott)
Assign Data Management and Biostatistics GmbH

Completed

Study to Evaluate the Effect of Intravenous (IV) Paricalcitol (Zemplar) on Cardiac Morbidity in Patients With Chronic Kidney Disease (CKD) Stage 5 Over 2 Years

Secondary Hyperparathyroidism | Chronic Kidney Disease Stage V | Cardiac Morbidity

Austria
Amgen

Completed

SENSOR: Study to Investigate Cinacalcet Treatment in Haemodialysis Patients With Secondary Hyperparathyroidism

End Stage Renal Disease | Secondary Hyperparathyroidism
Amgen

Completed

Cinacalcet Study to Reach Kidney Disease Outcomes Quality Initiative (K/DOQI) Levels

End Stage Renal Disease
Amgen

Completed

A Study of Cinacalcet to Improve Achievement of National Kidney Foundation Kidney Disease Outcomes Quality Initiative (K/DOQI) Targets in Patients With End Stage Renal Disease (ESRD)

Anemia | Secondary Hyperparathyroidism
Skane University Hospital
Karolinska University Hospital

Completed

Morbidity Related to Secondary Hyperparathyroidism After Renal Transplantation (SHPT-RT)

Secondary Hyperparathyroidism | Disorder Related to Renal Transplantation
Eli Lilly and Company
TransPharma Medical

Completed

A Study for the Transdermal Application of Teriparatide

Osteoporosis

Hungary, Romania, Mexico, Argentina, Estonia
Abbott

Completed

Evaluation of the Effectiveness of Paricalcitol Versus Cinacalcet With Low-Dose Vitamin D (IMPACT SHPT)

Hemodialysis | Chronic Kidney Disease | Secondary Hyperparathyroidism

United States, Czech Republic, Denmark, Germany, Greece, Italy, Netherlands, Portugal, Russian Federation, Spain, Sweden, United Kingdom
ENRICO VERRINA

Unknown

Cinacalcet in Paediatric Secondary Hyperparathyroidism (SHPT) Due to Chronic Kidney Disease (CKD)

Secondary Hyperparathyroidism

Italy
Amgen

Completed

A Research Study for Patients With End-Stage Renal Disease (ESRD)

End Stage Renal Disease

Search clinical trials for: sHPT

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Singapore

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations